[ad_1]
Intervals "Pfizer" It plans to apply for approval of its use from the Food and Drug Administration as soon as safety data allows, possibly starting the third week of November.
However, the launch of the vaccine in some countries will be affected by their infrastructure and the availability of storage capacities under certain conditions, the most important of which is the availability of temperature-setting refrigerators. "Negative 80" Needed to save it.
Their availability will also depend on the volume of their production, which must be done at enormous levels.
And two companies are concluded "Pfizer" Y"Bountech" A $ 1.95 billion contract with the United States government to supply 100 million doses of vaccine earlier this year, and they have also reached supply agreements with the European Union, Great Britain, Canada and Japan, which appear to be the first to receive it.
How close is the world to success when facing Corona?
After showing no signs of safety problems and with the participation of volunteers of various backgrounds, a vaccine appears "Pfizer" وبيونتك" On his way to overcome the necessary health conditions before obtaining the approval of the competent authorities.
And the researchers had previously confirmed that they would give the vaccine the green light, with an efficacy rate of at least 50 percent, a figure the new vaccine has already surpassed.
Most experts agree that the results of the new vaccine are excellent news, but optimism must be accompanied by an important note, which is that the results are still preliminary, they were only shared through a press release, while the scientific judgments are not yet complete.
It’s a company "Pfizer" His partner is the first pharmaceutical company to publish successful data from a large-scale clinical trial of a coronavirus vaccine.
The two companies said they had yet to encounter serious safety concerns and were hoping to get a U.S. permit this month to use the vaccine in emergency situations.
If they get permission, the number of doses will be limited at first and many questions remain unanswered, including the period during which the vaccine provides protection, but the news provides hope that vaccines "COVID-19" Others in development can also be effective.
Biden and the two companies comment
US President-elect Joe Biden said in a statement: "Today’s news is great, but it doesn’t change that fact. Today’s announcement heralds an opportunity to change that next year, but the tasks ahead now remain the same.".
Albert Burla CEO explained "Pfizer": "Today is a great day for science and humanity. We have reached this critical milestone in the vaccine development program at a time when the world desperately needs it, with infection rates setting new records, hospitals nearly full, and economies scrambling to reopen.".
Ugur Sahin, CEO of the company, said "Bountech" by"Reuters"He is optimistic that the vaccination effect of the vaccine will last for a year, although this is not yet confirmed.
As William Schaffner, an infectious disease expert at the University School of Medicine, said "Vanderbilt" In Nashville, Tennessee, that "The event data is really impressive. Better than most of us expected. The study is not complete yet, but the data appears to be very robust".
“>
On Monday, the two companies announced that their experimental vaccine to fight the disease “Covid 19” is more than 90 percent effective, representing a major victory in the battle against the epidemic that has killed more than a million people. , devastated the global economy and revolutionized the patterns of daily life.
But many questions remain that need to be answered, including how this vaccine works. When and where will it be available in its early stages? How close is the world to eliminating the epidemic?
How does it work?
Simply put, the new vaccine relies on a genetic material called “mRNA” that allows the body to make the proteins on the outside of the Corona virus, which give it its distinctive coronary shape.
The vaccine introduces this genetic material into the human body and stimulates human cells to produce the protein on the surface of the virus, making the body mistakenly feel that it has been exposed to infection by the virus, and in response to this , produces antibodies against the virus, and then other immune pathways are activated to protect against infection.
When and where will it be available?
The world will need some time before the vaccine is available, as it must obtain the approval of the competent health authorities.
“Pfizer” said it plans to submit an application to the US Food and Drug Administration for approval for use as soon as safety data allows, and that may happen in the third week of November.
However, the launch of the vaccine in some countries will be affected by their infrastructure and the availability of storage capacity under certain conditions, the most important of which is the availability of refrigerators that give the temperature of “minus 80” necessary to keep it.
Their availability will also depend on the volume of their production, which must be done at enormous levels.
Pfizer and Biontech concluded a $ 1.95 billion contract with the United States government to supply 100 million doses of vaccine earlier this year, and also reached supply agreements with the European Union, Great Britain, Canada, and Japan. who seem to be the first to receive it.
How close is the world to success when facing Corona?
After showing no signs of safety issues and with the participation of volunteers from various backgrounds, it appears that the “Pfizer” and Biontech “vaccine is on its way to circumvent the necessary health conditions before obtaining approval from the relevant authorities.
And researchers had previously confirmed that they would green-light the vaccine with an efficacy rate of at least 50 percent, a figure the new vaccine has already surpassed.
Most experts agree that the results of the new vaccine are excellent news, but optimism must be accompanied by an important note, which is that the results are still preliminary, they have only been shared through a press release. , while scientific trials have not yet been completed.
Pfizer and its partner are the first pharmaceutical companies to publish successful data from a large-scale clinical trial of a coronavirus vaccine.
The two companies said they had yet to encounter serious safety concerns and were hoping to get a U.S. permit this month to use the vaccine in emergency situations.
If they get permission, the number of doses will be limited at first and many questions remain unanswered, including the period during which the vaccine provides protection. However, the news raises hope that other “Covid 19” vaccines in development may also prove effective.
Biden and the two companies comment
US President-elect Joe Biden said in a statement: “Today’s news is wonderful, but it does not change this fact. Today’s announcement heralds an opportunity to change that next year, but the tasks that lie ahead now they remain as they are. “
“Today is a great day for science and humanity,” said Albert Burla, CEO of Pfizer.
Biontech CEO Ugur Shaheen told “Reuters” that he is optimistic that the vaccination effect of the vaccine will last for a year, although this is not yet confirmed.
As William Schaffner, an infectious disease expert at Vanderbilt University School of Medicine in Nashville, Tennessee, said, “The efficacy data is really impressive. This is better than most of us expected. The study is not in yet. complete, but the data looks very strong. “
[ad_2]
